US BANCORP \DE\ - ESPERION THERAPEUTICS INC NE ownership

ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 171 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.0%.

Quarter-by-quarter ownership
US BANCORP \DE\ ownership history of ESPERION THERAPEUTICS INC NE
ValueSharesWeighting
Q3 2023$1,061
-29.5%
1,0830.0%0.00%
Q2 2023$1,506
-23.0%
1,083
-12.0%
0.00%
Q1 2023$1,956
-91.6%
1,230
-67.1%
0.00%
Q4 2022$23,294
-44.5%
3,739
-40.0%
0.00%
Q3 2022$42,000
+16.7%
6,232
+10.3%
0.00%
Q2 2022$36,000
+71.4%
5,648
+25.7%
0.00%
Q1 2022$21,000
+250.0%
4,492
+247.1%
0.00%
Q4 2021$6,000
-89.1%
1,294
-71.7%
0.00%
Q3 2021$55,000
-45.5%
4,573
-4.6%
0.00%
Q2 2021$101,000
-34.0%
4,793
-11.9%
0.00%
Q1 2021$153,000
-64.5%
5,443
-67.1%
0.00%
-100.0%
Q4 2020$431,000
-47.5%
16,566
-25.0%
0.00%
-50.0%
Q3 2020$821,000
+101.2%
22,095
+178.1%
0.00%
+100.0%
Q2 2020$408,000
+81.3%
7,946
+11.3%
0.00%0.0%
Q1 2020$225,000
-38.9%
7,140
+15.9%
0.00%0.0%
Q4 2019$368,000
+231.5%
6,159
+103.3%
0.00%
Q3 2019$111,000
-22.9%
3,030
-2.3%
0.00%
Q2 2019$144,000
+16.1%
3,1000.0%0.00%
Q1 2019$124,000
-74.5%
3,100
-70.8%
0.00%
-100.0%
Q4 2018$487,000
+4.1%
10,600
+0.7%
0.00%
+100.0%
Q3 2018$468,000
-10.7%
10,530
-21.3%
0.00%
-50.0%
Q2 2018$524,000
-55.7%
13,378
-18.2%
0.00%
-50.0%
Q1 2018$1,182,000
+61.5%
16,346
+46.9%
0.00%
+100.0%
Q4 2017$732,000
+32.1%
11,124
+0.7%
0.00%0.0%
Q3 2017$554,000
+21.2%
11,051
+12.1%
0.00%0.0%
Q2 2017$457,000
+32.8%
9,856
+1.1%
0.00%
+100.0%
Q1 2017$344,000
+182.0%
9,7520.0%0.00%
Q4 2016$122,000
-9.6%
9,7520.0%0.00%
-100.0%
Q3 2016$135,000
-10.6%
9,752
-36.3%
0.00%0.0%
Q2 2016$151,000
-41.7%
15,3200.0%0.00%0.0%
Q1 2016$259,000
+37.0%
15,320
+80.2%
0.00%0.0%
Q4 2015$189,000
-23.8%
8,500
-19.0%
0.00%0.0%
Q3 2015$248,000
-71.2%
10,500
-0.2%
0.00%
-66.7%
Q2 2015$860,000
-11.5%
10,522
+0.2%
0.00%
-25.0%
Q1 2015$972,000
+128.7%
10,5000.0%0.00%
+100.0%
Q4 2014$425,00010,5000.00%
Other shareholders
ESPERION THERAPEUTICS INC NE shareholders Q1 2023
NameSharesValueWeighting ↓
Meditor Group Ltd 2,679,835$99,609,00022.32%
Bellevue Group AG 5,465,715$203,160,0002.81%
Rhenman & Partners Asset Management AB 455,000$16,912,0001.50%
Endurant Capital Management LP 135,901$5,051,0001.49%
Boxer Capital, LLC 975,000$36,241,0001.25%
DCF Advisers, LLC 56,500$2,100,0001.07%
Pentwater Capital Management LP 2,169,022$80,623,0001.04%
Nicholas Investment Partners, LP 235,855$8,767,0000.95%
Amia Capital LLP 20,464$761,0000.88%
HAMILTON LANE ADVISORS LLC 46,181$1,717,0000.83%
View complete list of ESPERION THERAPEUTICS INC NE shareholders